Agilent Technologies (NYSE:A) Price Target Lowered to $135.00 at Barclays

Agilent Technologies (NYSE:A) had its target price lowered by Barclays from $145.00 to $135.00 in a report released on Wednesday, MarketBeat.com reports. The brokerage currently has an underweight rating on the medical research company’s stock.

A has been the subject of a number of other reports. Sanford C. Bernstein lowered their price target on Agilent Technologies from $140.00 to $135.00 and set a “market perform” rating for the company in a report on Tuesday. UBS Group increased their price target on Agilent Technologies from $141.00 to $150.00 and gave the stock a “neutral” rating in a report on Thursday, August 22nd. Stifel Nicolaus reiterated a “buy” rating and set a $151.00 price target on shares of Agilent Technologies in a report on Monday, August 26th. Evercore ISI increased their price target on Agilent Technologies from $135.00 to $145.00 and gave the stock an “in-line” rating in a report on Tuesday, October 1st. Finally, TD Cowen raised their target price on Agilent Technologies from $153.00 to $160.00 and gave the company a “buy” rating in a report on Thursday, August 22nd. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, Agilent Technologies has an average rating of “Hold” and a consensus price target of $143.40.

Agilent Technologies Stock Up 2.8 %

Shares of A opened at $138.11 on Wednesday. The company has a market capitalization of $39.68 billion, a PE ratio of 31.25, a price-to-earnings-growth ratio of 5.91 and a beta of 1.07. The company has a quick ratio of 1.37, a current ratio of 1.78 and a debt-to-equity ratio of 0.36. Agilent Technologies has a 52-week low of $124.10 and a 52-week high of $155.35. The stock has a fifty day simple moving average of $137.72 and a two-hundred day simple moving average of $137.43.

Agilent Technologies Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, January 22nd. Stockholders of record on Tuesday, December 31st will be given a dividend of $0.248 per share. This represents a $0.99 annualized dividend and a dividend yield of 0.72%. The ex-dividend date of this dividend is Tuesday, December 31st. This is a positive change from Agilent Technologies’s previous quarterly dividend of $0.24. Agilent Technologies’s dividend payout ratio (DPR) is 21.27%.

Insider Transactions at Agilent Technologies

In other Agilent Technologies news, SVP Dominique Grau sold 9,990 shares of the business’s stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $145.00, for a total transaction of $1,448,550.00. Following the sale, the senior vice president now directly owns 40,011 shares in the company, valued at approximately $5,801,595. The trade was a 19.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Hedge Funds Weigh In On Agilent Technologies

Several institutional investors have recently added to or reduced their stakes in A. Massachusetts Financial Services Co. MA increased its stake in Agilent Technologies by 5.7% in the second quarter. Massachusetts Financial Services Co. MA now owns 15,064,660 shares of the medical research company’s stock valued at $1,952,832,000 after purchasing an additional 809,149 shares during the last quarter. FMR LLC grew its position in Agilent Technologies by 62.2% during the third quarter. FMR LLC now owns 1,287,665 shares of the medical research company’s stock valued at $191,193,000 after acquiring an additional 493,947 shares during the period. Worldquant Millennium Advisors LLC purchased a new stake in Agilent Technologies during the third quarter valued at about $49,449,000. Marshall Wace LLP grew its position in Agilent Technologies by 48.6% during the second quarter. Marshall Wace LLP now owns 957,128 shares of the medical research company’s stock valued at $124,073,000 after acquiring an additional 313,155 shares during the period. Finally, Jennison Associates LLC grew its position in Agilent Technologies by 63.3% during the third quarter. Jennison Associates LLC now owns 586,439 shares of the medical research company’s stock valued at $87,075,000 after acquiring an additional 227,431 shares during the period.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.